APOE4 binds TREM2 with lower affinity than APOE3, driving microglia toward a neurodegenerative phenotype with failed DAM1→DAM2 transition. Anti-APOE4 antibodies (3H9) shift microglial phenotype to neuroprotective state. This hypothesis benefits from APOE4 being the strongest AD genetic risk factor after PSEN1/APP. However, the single-cell transcriptomics literature now identifies at least four microglial states beyond the binary DAM framework, suggesting the mechanism is oversimplified.
Curated pathway from expert analysis
flowchart TD
A["APOE4 Isoform<br/>vs APOE3"]
B["Reduced Amyloid<br/>Clearance"]
C["Enhanced Neurofibrillary<br/>Tangle Formation"]
D["Blood-Brain Barrier<br/>Breakdown"]
E["Tau-Mediated<br/>Neuronal Loss"]
F["Lipid Transport<br/>Dysregulation"]
G["Synaptic<br/>Dysfunction"]
H["Cognitive<br/>Decline"]
A --> B
B --> C
A --> F
F --> C
C --> D
D --> E
E --> G
G --> H
style A fill:#6a1b9a,stroke:#ce93d8,color:#ce93d8
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9aNo linked papers recorded for this hypothesis yet.
Median TPM across 13 brain regions for APOE from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for APOE.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF APOE4/4 iPSC-derived microglia are treated with 3H9 anti-APOE4 antibody (10 μg/mL for 48 hours), THEN cellular ATP levels will increase by ≥40% and phagocytic index (pHrodo-labeled amyloid-β42 upta | ≥40% increase in cellular ATP (measured by CellTiter-Glo) and ≥50% improvement in phagocytic index (flow cytometry MFI) for amyloid-β42 uptake in antibody-treat | — no observation — | pending | 0.62 |
| IF anti-APOE4 antibody (3H9) is administered weekly for 12 weeks to APOE4/4 homozygous individuals with early-stage Alzheimer's disease, THEN cerebrospinal fluid levels of TREM2 ectodomain will increa | ≥30% increase in CSF TREM2 ectodomain concentration and >25% reduction in APOE4-associated neurodegenerative microglial gene signature score (including CD36, TR | — no observation — | pending | 0.45 |